Bristol Myers Squibb bought Turning Point Therapeutics Turning Point Therapeutics from 8/17/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Bristol Myers Squibb has completed its acquisition of Turning Point Therapeutics for $4.1 billion, or $76 per share.

Turning Point Therapeutics

Review

Source:

{source} pictogram

Vladimir Petenev

News editor

Write your comment first

News feed

IFC Zaimer specified the date of register closing for dividends

12/6/24 ZAYM

Smartofood successfully closed the round of investment attraction

12/6/24 OTCI

Element Group prepares to launch ₽10 billion investment fund

12/6/24 ELMT

Sberbank to launch services for buying and selling cars

12/6/24 SBER

Shareholders of Novorossiysk Bakery Products Plant approved dividends

12/6/24 NKHP

Sberbank gave forecasts for 2025

12/6/24 SBER

Lenta opened a hypermarket ‘Economy’ in Chelyabinsk

12/6/24 LENT

Board of Directors of Perm Energy Supply Company recommended dividends

12/6/24 PMSB

Ozone Pharmaceuticals has launched a generic of Rivaroxaban on the market

12/6/24 OZPH

Positive Technologies has entered the Egyptian market

12/6/24 POSI